FTSE 100 news / Companies and sectors / GSK / RBC expects GSK Q3 results in line
RBC expects GSK Q3 results in line
+0.1 neutral
RBC expects in-line Q3 as vaccine weakness is offset by HIV and respiratory strength, and holds Neutral.
How each outlet covered it
| Outlet | Headlines | Tone |
|---|---|---|
| Pluang | 1 | +1.7 |
| Proactive financial news | 1 | +0.8 |
| Yahoo Finance | 1 | +0.3 |
| MarketScreener | 1 | 0.0 |
| Proactive Investors UK | 1 | −2.5 |
Day by day
Wednesday 14 October 2026
RBC expects in-line Q3 as vaccine weakness is offset by HIV and respiratory strength, and holds Neutral.
- −2.5 RBC holds on GSK ahead of third-quarter results as HIV cliff looms
RBC holds, warns of looming HIV cliff. - +1.7 GSK Q3 results expected in line as vaccine weakness offset by HIV and respiratory drug strength
In-line Q3 expected; vaccine weakness offset by HIV and respiratory. - +0.8 GSK third quarter likely to be in line as RBC sees vaccine headwinds offset by HIV strength
In-line quarter expected with vaccine headwinds offset by HIV. - +0.3 GSK Likely to Deliver In-Line Q3, RBC Says
Analyst expects in-line quarter; neutral. - 0.0 GSK plc : RBC gives a Neutral rating
RBC Neutral rating maintained.